Loss of cold shock domain-containing protein E1 (CSDE1) function enhances mRNA stability of interleukin-6 and promotes malignant transformation in endometrial cancer cells Authors: Yuanlin Liu, Lianqiao Qiao, Xiaoli Wen, Mengfei Wang, Junyuan Li, Yan Ding, Han Tao, Yilin Dai, Luhui Wang, Kun Gao, Xiaoping Wan Published: 2026 ABSTRACT BackgroundRNA-binding proteins (RBPs) are indispensable effectors of post-transcriptional gene regulation and are increasingly recognized as pivotal modulators of oncogenic signaling pathways. Cold shock domain-containing protein E1 (CSDE1) has been reported to be dysregulated or mutated in several malignancies; however, its functional significance and the mechanistic basis of its involvement in endometrial cancer (EC) progression remain poorly understood.MethodsBioinformatic analysis of The Cancer Genome Atlas (TCGA) was employed to characterize CSDE1 expression and mutation profiles in EC. CRISPR/Cas9-mediated knockout (KO) was used to establish CSDE1-deficient EC cell lines. The impact on cell proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) was evaluated through standard functional assays. To identify downstream targets, transcriptomic profiling was integrated with RNA-protein interaction assay and mRNA stability analysis. Finally, functional rescue experiments were conducted using shRNA-mediated IL-6 silencing and pharmacological inhibition with the IL-6 antagonist Siltuximab.ResultsCSDE1 is frequently mutated and significantly downregulated in EC tissues compared to normal controls. Loss of CSDE1 markedly accelerated EC cell proliferation, migration, invasion, and the acquisition of EMT-associated phenotypes. Transcriptomic analysis identified IL-6 as a prominent downstream target that is significantly upregulated upon CSDE1 depletion. Mechanistically, CSDE1 directly binds to IL-6 mRNA and negatively regulates its stability, thereby restraining IL-6 expression. Notably, both genetic silencing of IL-6 and pharmacological neutralization of IL-6 signaling with Siltuximab effectively abrogated the aggressive malignant phenotypes induced by CSDE1 loss.ConclusionsThese findings establish CSDE1 as a novel tumor suppressor in EC and elucidate a previously unrecognized post-transcriptional CSDE1–IL-6 regulatory axis. By linking RBP-mediated mRNA stability to oncogenic inflammatory signaling, our study provides critical insights into the molecular drivers of EC progression. Furthermore, we identify the IL-6 signaling pathway as a significant therapeutic vulnerability that could be exploited to treat CSDE1-deficient EC.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12964-026-02960-7. Introduction Endometrial cancer (EC) is the most prevalent gynecologic malignancy in developed countries, with both its incidence and mortality rates rising steadily in recent years. In 2025, over 69,000 new cases and nearly 14,000 deaths were projected in the United States alone, reflecting annual increases of approximately 1.3% and 1.5%, respectively. Despite significant advances in early diagnosis and surgical interventions, the prognosis for advanced or metastatic EC remains dismal. These cases, often characterized by lymph node involvement or distant organ dissemination, are associated with a 5-year survival rate of less than 20% [1]. Traditionally, EC is categorized into two distinct classes: Type I (endometrioid) and Type II (non-endometrioid). Type I tumors represent roughly 80% of diagnoses and are characteristically driven by the oncogenic effects of unopposed estrogen stimulation [1, 2]. While molecular profiling, particularly the advent of TCGA-defined subtypes, has significantly refined diagnostic and therapeutic stratification [2], several clinical hurdles remain. Persistent treatment resistance, the lack of globally standardized regimens, and dismal outcomes in advanced disease underscore a critical imperative to elucidate the mechanisms driving metastasis and to identify novel therapeutic targets [2, 3]. Cold shock domain-containing protein E1 (CSDE1), also known as upstream of N-Ras (UNR), is an evolutionarily conserved RNA-binding protein (RBP) that orchestrates post-transcriptional gene regulation [4]. By modulating mRNA stability and translational efficiency, CSDE1 serves as a master regulator of diverse biological programs, including epithelial-mesenchymal transition (EMT), stem cell maintenance, erythropoiesis, and synaptic plasticity [5]. Intriguingly, CSDE1 exhibits context-dependent functional duality, acting as either an oncogene or a tumor suppressor across different malignancies [6]. While it drives invasion and metastasis in certain cancers, CSDE1 paradoxically suppresses tumor growth in others, such as squamous cell carcinoma, by stabilizing tumor-suppressive transcripts or repressing oncogenic translation [5, 7]. In EC, CSDE1 mutations are common, particularly in the ultramutated POLE molecular subtype, with alterations occurring in approximately 10% of cases [8–10]. Despite this prominent mutational landscape, the functional contribution of CSDE1 to EC progression remains poorly defined, and the molecular mechanisms underlying its putative tumor-suppressive role are yet to be fully elucidated [11]. Interleukin-6 (IL-6) is a pleiotropic cytokine implicated in immune regulation [12, 13], inflammation [14], and cancer progression [15–17]. Elevated IL-6 expression has been associated with poor prognosis in several malignancies [18, 19], including breast, ovarian, and liver cancers, in which it activates key oncogenic signaling pathways such as JAK-STAT3 [20], PI3K-Akt, and MAPK [21–23]. In EC, IL-6 has been shown to promote tumor growth, metastasis, and immune evasion [24, 25]. Given its central role in tumor progression [4, 26, 27], IL-6 has emerged as a promising target in cancer [28, 29]. In the present study, we elucidate the role of CSDE1 as a potent tumor suppressor in EC, acting through the post-transcriptional regulation of IL-6 mRNA stability. We demonstrate that CSDE1 depletion accelerates EC cell proliferation, migration, and invasion, a phenotype concomitantly driven by the upregulation of IL-6. Mechanistically, our data reveal that CSDE1 directly binds to the IL-6 transcript to promote its decay, thereby restraining oncogenic signaling. These findings establish the CSDE1–IL-6 axis as a central determinant of EC pathogenesis and highlight IL-6 signaling as a promising therapeutic vulnerability in CSDE1-deficient tumors. Methods TCGA database acquisition and analysis EC-related expression profiles, somatic mutations, and clinical information were sourced from cBioPortal (http://www.cbioportal.org/) and the UALCAN platform (http://ualcan.path.uab.edu/). Transcriptomic data normalization and differential expression analysis were conducted using the edgeR package within the R/Bioconductor environment. Patient cohort and ethics statement Ethical approval for this study was granted by the Ethics Committee of Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine (No. KS25165), and written informed consent was obtained from all subjects. Diagnosis was histologically confirmed by two independent pathologists for all included EC samples. Crucially, all patients were naive to preoperative therapy, including endocrine therapy, radiotherapy, and chemotherapy, ensuring the specimens reflect the baseline molecular profile of the disease. Cell culture and lentiviral infection Human EC cell lines (Ishikawa, KLE, HEC-1 A [ATCC Cat# HTB-112, RRID: CVCL_0293], SPEC-2, AN3CA and HEC-1B [ATCC Cat# HTB-113, RRID: CVCL_0294]) and 293T cells were maintained in our laboratory (purchased from the Chinese Academy of Sciences) and cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin at 37 °C in a humidified incubator with 5% CO₂. The chemical reagents and antibodies used in this study are listed in Table S4. To generate lentiviral particles, shRNA plasmids (Genomeditech) and packaging constructs were transfected into 293T cells. Forty-eight hours after transfection, the viral supernatant was collected and used to infect target cells with the aid of polybrene. Infected cells were then cultured in medium containing 1 µg/mL Kasugamycin for three days for selection. The shRNA sequences used are listed in the Table S5. CRISPR-Cas9-mediated generation of KO cell lines Gene KO cell lines were established through CRISPR/Cas9-mediated genome editing. The pCRISPR-LvSG06 plasmid containing sgRNA targeting CSDE1 (purchased from Shanghai FulenGen Bio-Tech Co., Ltd.) was transfected into Ishikawa and HEC-1B cells. Forty-eight hours after transfection, cells were subjected to selection with 1 µg/mL puromycin for three days. Surviving cells were plated into 96-well plates using a limited dilution method to isolate monoclonal cell lines. KO clones were screened by western blotting and validated by Sanger sequencing. The specific sgRNA sequences targeting CSDE1 are listed in Table S5. RT-qPCR assay Total RNA was isolated from cells using TRIzol reagent (Thermo Fisher Scientific) according to standard procedures.The cDNA was synthesized from purified RNA using the PrimeScript RT Master Mix kit (TAKARA) according to the manufacturer’s instructions. Quantitative PCR was performed on an Eppendorf Mastercycler® ep realplex instrument using SYBR Premix Ex Taq (TAKARA). Gene expression levels were normalized to GAPDH as the endogenous control. The primer sequences used for RT-qPCR are listed in Supplementary Table S6. All experiments were performed in biological triplicate. RNA-seq and data analysis Total RNA was extracted from parental Ishikawa cells and CSDE1 KO cells using TRIzol reagent (Invitrogen, USA). Libraries were prepared for PE150 on the Illumina NovaSeq 6000 platform by Shanghai ApexBio Technology Co., Ltd. Differentially expressed genes (DEGs) were identified using DESeq2 (for samples with replicates) with cutoffs of |log₂ fold-change| ≥ 0.25 and p < 0.05. Significant DEGs and candidate genes from key modules were subjected to Gene Ontology (GO, http://www.geneontology.org/) and KEGG (https://www.kegg.jp/) pathway enrichment analyses using the ClusterProfiler package, with p < 0.05 considered significant. The RNA-seq data have been deposited in the Gene Expression Omnibus (GEO) under accession number GSE310724. IF and confocal microscopy Cells were plated on chamber slides and fixed with 4% paraformaldehyde at room temperature for 20 min. After washing with PBS, they were permeabilized in PBS containing 0.1% Triton X-100 for 15 min at room temperature. After an additional PBS wash, cells were blocked with 3% BSA for 1 h at room temperature and then incubated overnight at 4 °C with primary antibodies. The next day, cells were washed with PBS and incubated in the dark with fluorescence-conjugated secondary antibodies for 1 h at room temperature. Nuclei were stained with DAPI for 10 min. Samples were then imaged using either a fluorescence microscope or a Zeiss confocal laser scanning microscope. All primary and secondary antibodies used for IF are listed in Table S4. ELISA assay The culture supernatants from parental and CSDE1 KO Ishikawa and HEC-1B cells were collected and centrifuged at 1000 rpm for 20 min at 4 °C. The resulting supernatants were then used to measure IL-6 concentrations using an ELISA kit (ab178013, abcam) according to the manufacturer’s instructions. Optical density of each well was determined within 20 min using a microplate reader set to 450 nm. Cell proliferation assay Cell proliferation was assessed using the CCK-8 kit (Dojindo) according to the manufacturer’s instructions. Cells were seeded into 96-well plates at a density of 1000 cells per well and cultured for 1–4 days. Then, 10 µl of CCK-8 solution was added to each well, followed by incubation at 37 °C for 2 h. The absorbance was measured at 450 nm using a multimode plate reader (Molecular Devices, USA) to evaluate the colorimetric change. Each treatment was performed in triplicate, and the experiments were independently repeated more than three times. Colony formation assay Cells were seeded into 6-well plates at a density of 200 cells per well and cultured for 2 weeks. Once visible colonies had formed, they were fixed with 4% paraformaldehyde at room temperature for 10 min, stained with 0.5% crystal violet at room temperature for 30 min, and then photographed. All experiments were performed in triplicate and repeated at least three times. EdU incorporation assay DNA synthesis was assessed using an EdU Cell Proliferation Kit with Alexa Fluor 555 (Beyotime, China). Cells were seeded in 96-well plates, and the assay was performed according to the manufacturer’s instructions. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI). Images were captured using a confocal microscope (Olympus, Japan). Cell migration and invasion assay Cells were serum-starved for 48 h, trypsinized, and then seeded into the upper chamber of Transwell inserts (Corning, USA) at densities of 6 × 10^5 Ishikawa cells or 3 × 10^4 HEC-1B cells in 200 µl serum-free DMEM. The lower chamber was filled with 600 µl DMEM containing 10% FBS. After 48 h incubation, cells on the upper side of the membrane were removed with a cotton swab. The migrated/invaded cells on the underside were fixed with 4% paraformaldehyde at room temperature for 10 min, stained with 0.5% crystal violet at room temperature for 30 min, and then imaged and counted under a light microscope. For invasion assay, the upper chamber membrane was pre-coated with 30 µg per well of Matrigel (BD, USA) according to the manufacturer’s instructions, and all other steps were identical to the migration assay. RIP assay RIP assay was performed according to established protocols. Briefly, 5 × 10^7 cells were collected and lysed in an ice-cold lysis buffer. Protein A magnetic beads (HY-K0202, MCE) and Protein G magnetic beads (HY-K0202, MCE) were each pre-incubated with 3 µg of the indicated antibody under end-over-end rotation for at least 6 h. Cleared lysates were then combined with the antibody-coated beads and rotated overnight in RIP buffer to allow immune complexes to form. RNA was subsequently purified using RNAiso Plus reagent. Antibody details are listed in Table S4. Actinomycin D-mediated RNA stability assay To evaluate transcript turnover, cells were seeded in six-well plates and cultured to approximately 70% confluence. Transcription was then inhibited by the addition of 5 µg/mL actinomycin D (Sigma-Aldrich) dissolved in DMSO, while vehicle-treated cells (DMSO alone) served as the control. Total RNA was isolated at specified time points (0, 1, 2, 4, and 6 h) post-treatment using TRIzol reagent (Invitrogen) following the manufacturer’s instructions. RNA concentration and purity were assessed spectrophotometrically, followed by cDNA synthesis using the PrimeScript RT Master Mix (TaKaRa). Quantitative PCR was performed on a CFX96 Real-Time PCR Detection System (Bio-Rad) using SYBR Green Master Mix (Applied Biosystems) to determine gene-specific transcript levels. The relative abundance of mRNA was normalized to GAPDH as an internal control, with the 0 h time point defined as the baseline (100%). RNA decay kinetics and half-lives were calculated by fitting the data to a first-order exponential decay model. All experiments were performed in biological triplicate. IHC analysis Formalin-fixed, paraffin-embedded (FFPE) tissue Sect. (4 μm thick) were prepared and processed according to established protocols. Briefly, slides were deparaffinized, rehydrated, and incubated in 3% H₂O₂ to quench endogenous peroxidase activity, followed by heat-induced antigen retrieval and blocking with BSA. Sections were then incubated overnight at 4 °C with primary antibodies, and stained using a DAB detection kit (KIT9710, MXB Biotechnologies). Three independent pathologists, blinded to all clinical and clinicopathological data, evaluated each slide. Immunoreactivity was scored semi-quantitatively by integrating a proportion score (0: 0–5%, 1: 6–25%, 2: 26–50%, 3: 51–75%, 4: 76–100%) and an intensity score (0: none, 1: weak, 2: moderate, 3: strong). The final IHC score (IS) for each specimen was calculated as the product of these two values (Table S8). In vivo xenograft tumor assay All animal procedures were conducted in accordance with the protocols approved by the Animal Ethics Committee of Tongji University (No. TJBG26325101). Female BALB/c nude mice (4–6 weeks old), sourced from Shanghai Southern Model Biological Technology Co., Ltd., were maintained under specific pathogen-free (SPF) conditions with ad libitum access to food and water. For xenograft establishment, 1 × 10⁶ parental or CSDE1 KO Ishikawa cells were suspended in 100 µL of sterile PBS and subcutaneously injected into the lateral flank of each mouse. Each experimental group consisted of six mice. Once tumor volumes reached approximately 50 mm³ (typically around day 13 post-inoculation), cohorts bearing tumors from either parental or CSDE1-deficient cells were administered intraperitoneal injections of Siltuximab (10 mg/kg in 0.1 mL PBS). The control groups received an equal volume of PBS alone. Tumor progression was monitored every three days by measuring two perpendicular diameters with a digital caliper. Tumor volumes were calculated using the standard ellipsoid formula: V = (L × W²)/2, where L represents tumor length and W represents width. Statistical analysis All statistical evaluations were performed using GraphPad Prism version 7.0 (GraphPad Software). Each experiment was independently repeated at least three times. Data are expressed as mean ± standard deviation (SD). Comparisons between two groups were carried out using Student’s t-test, while comparisons among multiple groups were analyzed using either one-way ANOVA, two-way ANOVA, or the Pearson Chi-square test, as appropriate and unless otherwise noted. Statistical significance was defined as follows: *p < 0.05, **p < 0.01, and ***p < 0.001. Results CSDE1 is frequently mutated and downregulated in EC To evaluate the genomic landscape of CSDE1 in EC, we first analyzed its genetic alterations in the TCGA-UCEC cohort. Our analysis revealed a high frequency of CSDE1 mutations and copy-number losses, with alterations occurring in approximately 10% of EC cases (Fig. S1A, B). Notably, UCEC exhibited the highest frequency of CSDE1 genetic alterations among all analyzed TCGA pan-cancer cohorts (Fig. S1A). Specifically, a total of 55 missense mutations and 14 truncating mutations were identified, indicating that CSDE1 inactivation is a frequent event in EC (Fig. 1A). These mutations were distributed throughout the coding sequence, with truncating mutations accounting for a significant proportion of the identified alterations (Fig. 1B). Fig. 1CSDE1 is frequently mutated and downregulated in EC. A OncoPrint summary of CSDE1 genetic alterations. Each column represents an individual tumor sample from the TCGA-UCEC cohort, with color-coding indicating specific types of alterations, such as inframe, missense, and truncating mutations, as well as amplifications and deep deletions, based on data from www.cbioportal.org. B Schematic representation of the CSDE1 protein structure highlighting the positions of somatic mutations identified in the TCGA-UCEC cohort. All variants shown are coding (exonic) variants from TCGA WXS dataset; noncoding variants were not included. C Relative CSDE1 mRNA expression of in normal endometrial tissues and EC tissues from the TCGA-UCEC cohort, based on data from www.ualcan.path.uab.edu. D CSDE1 mRNA expression in different histological subtypes of EC from the TCGA-UCEC cohort. E CSDE1 mRNA expression in EC across different pathological stages from the TCGA-UCEC cohort. F, G Co-occurrence of CSDE1 and POLE mutations in the TCGA-UCEC cohort, with significant statistical analysis. H, I IHC analysis of CSDE1 protein expression in normal endometrial tissues (left) and EC tissues (right). 200× magnification, scale bar = 100 μm. 400× magnification, scale bar = 50 μm. (I) Quantitative data for CSDE1 protein expression from IHC analysis, comparing normal endometrial (n = 49) and EC tissues (n = 49). Statistical significance was calculated using the Two-way ANOVA test in (C, D, E, I). *p < 0.05. **p < 0.01. ***p < 0.001. ****p < 0.0001. ns, not significant CSDE1 is frequently mutated and downregulated in EC. A OncoPrint summary of CSDE1 genetic alterations. Each column represents an individual tumor sample from the TCGA-UCEC cohort, with color-coding indicating specific types of alterations, such as inframe, missense, and truncating mutations, as well as amplifications and deep deletions, based on data from www.cbioportal.org. B Schematic representation of the CSDE1 protein structure highlighting the positions of somatic mutations identified in the TCGA-UCEC cohort. All variants shown are coding (exonic) variants from TCGA WXS dataset; noncoding variants were not included. C Relative CSDE1 mRNA expression of in normal endometrial tissues and EC tissues from the TCGA-UCEC cohort, based on data from www.ualcan.path.uab.edu. D CSDE1 mRNA expression in different histological subtypes of EC from the TCGA-UCEC cohort. E CSDE1 mRNA expression in EC across different pathological stages from the TCGA-UCEC cohort. F, G Co-occurrence of CSDE1 and POLE mutations in the TCGA-UCEC cohort, with significant statistical analysis. H, I IHC analysis of CSDE1 protein expression in normal endometrial tissues (left) and EC tissues (right). 200× magnification, scale bar = 100 μm. 400× magnification, scale bar = 50 μm. (I) Quantitative data for CSDE1 protein expression from IHC analysis, comparing normal endometrial (n = 49) and EC tissues (n = 49). Statistical significance was calculated using the Two-way ANOVA test in (C, D, E, I). *p < 0.05. **p < 0.01. ***p < 0.001. ****p < 0.0001. ns, not significant Analysis of clinical datasets revealed a significant reduction in CSDE1 mRNA expression in EC tissues compared with normal endometrial tissues, underscoring its downregulation at the transcript level (Fig. 1C). Furthermore, this low expression of CSDE1 was consistently observed across various histological subtypes, tumor grades, and clinical stages of EC (Fig. 1D, E). Notably, CSDE1 mutations were significantly enriched in the POLE ultramutated subtype, suggesting a potential association between CSDE1 alterations and specific molecular subclasses of EC (Fig. 1F, G). Consistent with the transcriptomic data, IHC analysis of primary EC specimens confirmed that CSDE1 protein levels were markedly downregulated in malignant tissues compared with adjacent normal tissues (Fig. 1H, I). Collectively, these findings demonstrate that CSDE1 is frequently mutated and downregulated in EC, supporting its putative role as a tumor suppressor in this malignancy. Loss of CSDE1 promotes the proliferative and metastatic potential of EC cells To explore the functional significance of CSDE1 in EC progression, we first characterized its endogenous expression across a panel of EC cell lines. Among the EC cell lines screened, Ishikawa and HEC-1B cells displayed comparatively elevated CSDE1 expression, leading to their selection for subsequent KO experiments (Fig. 2A). Notably, cross-referencing the CCLE and DepMap databases confirmed an absence of exonic CSDE1 mutations in these lines, including the low-expressing AN3CA cells, suggesting that observed expression variations are likely driven by non-mutational mechanisms. Fig. 2CSDE1 loss promotes cell growth, migration, and invasion in EC cells. A Western blot of CSDE1 protein expression in whole cell lysates (WCLs) from six EC cell lines. B Western blot of CSDE1 protein expression in WCLs from Ishikawa cells with two independent CSDE1 KO clones by CRISPR-Cas9 methods. C, D CCK-8 cell proliferation assay of parental and CSDE1 KO Ishikawa (C) and HEC-1B (D) cells. Data are shown as mean ± SD (n = 3). E Colony formation assay of parental and CSDE1 KO Ishikawa and HEC-1B cells. Data are shown as mean ± SD (n = 3). Scale bar, 100 μm. F, G EdU incorporation assay of parental and CSDE1 KO Ishikawa and HEC-1B cells. The quantitative data are shown in G. Data are shown as mean ± SD (n = 3). Scale bar, 100 μm. H, I Transwell migration and invasion assays of parental and CSDE1 KO Ishikawa and HEC-1B cells. Quantitative data are shown in (H). Data are shown as mean ± SD (n = 3). Scale bar, 100 μm. Statistical significance was calculated using the Two-way ANOVA test in (C, D, E, G, H). *p < 0.05. **p < 0.01. ***p < 0.001. ****p < 0.0001. ns, not significant CSDE1 loss promotes cell growth, migration, and invasion in EC cells. A Western blot of CSDE1 protein expression in whole cell lysates (WCLs) from six EC cell lines. B Western blot of CSDE1 protein expression in WCLs from Ishikawa cells with two independent CSDE1 KO clones by CRISPR-Cas9 methods. C, D CCK-8 cell proliferation assay of parental and CSDE1 KO Ishikawa (C) and HEC-1B (D) cells. Data are shown as mean ± SD (n = 3). E Colony formation assay of parental and CSDE1 KO Ishikawa and HEC-1B cells. Data are shown as mean ± SD (n = 3). Scale bar, 100 μm. F, G EdU incorporation assay of parental and CSDE1 KO Ishikawa and HEC-1B cells. The quantitative data are shown in G. Data are shown as mean ± SD (n = 3). Scale bar, 100 μm. H, I Transwell migration and invasion assays of parental and CSDE1 KO Ishikawa and HEC-1B cells. Quantitative data are shown in (H). Data are shown as mean ± SD (n = 3). Scale bar, 100 μm. Statistical significance was calculated using the Two-way ANOVA test in (C, D, E, G, H). *p < 0.05. **p < 0.01. ***p < 0.001. ****p < 0.0001. ns, not significant We then employed CRISPR-Cas9 technology to generate CSDE1 KO clones in both the Ishikawa and HEC-1B backgrounds, utilizing two independent single-guide RNAs (sgRNAs) to ensure robust gene disruption (Fig. S1C, D). Complete depletion of the CSDE1 protein expression in these KO clones was validated by Western blot analysis (Fig. 2B; Fig. S1E). To evaluate the impact of CSDE1 loss on cellular behavior, we performed a series of functional assays. The CCK-8 assay demonstrated that CSDE1 KO significantly accelerated cell proliferation compared to parental counterparts (Fig. 2C, D). This heightened proliferative potential was further supported by colony formation assays, where CSDE1 KO Ishikawa cells yielded substantially more colonies than parental cells (Fig. 2E). Furthermore, EdU incorporation assays confirmed a marked increase in DNA synthesis in CSDE1 KO Ishikawa cells, reinforcing the role of CSDE1 as a negative regulator of cell cycle progression (Fig. 2F, G). Next, we investigated the effect of CSDE1 loss on migration and invasion, two fundamental hallmarks of cancer metastasis. Transwell assay revealed that CSDE1 KO significantly enhanced both the migratory and invasive capabilities of Ishikawa and HEC-1B cells (Fig. 2H, I). These findings indicate that the loss of CSDE1 facilitates the acquisition of aggressive metastatic traits in EC cells. Collectively, the enhanced proliferative and metastatic phenotypes observed upon CSDE1 KO strongly suggest that its loss plays a important role in promoting EC malignancy. CSDE1 deficiency triggers molecular and morphological reprogramming indicative of EMT in EC cells To elucidate the molecular mechanisms underlying the phenotypic changes induced by CSDE1 loss, we performed genome-wide transcriptome profiling via RNA-seq on parental and CSDE1 KO Ishikawa cells. Analysis identified 2,618 differentially expressed genes (DEGs) in CSDE1 KO Ishikawa cells, comprising 1,093 upregulated and 1,525 downregulated transcripts(|log₂ fold-change| ≥ 0.25, p < 0.05) (Fig. 3A, Table S1). This extensive transcriptional reprogramming suggests that CSDE1 loss impacts diverse cellular pathways. Gene Ontology (GO) analysis revealed that these DEGs were significantly enriched in pathways associated with cancer progression, including the PI3K–Akt, MAPK, and NF-κB signaling pathways (Fig. 3B, Table. S2). These findings were further supported by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis (Fig. 3C, Table. S3). Fig. 3CSDE1 KO induces molecular and morphological changes indicative of EMT in EC cells. A Volcano plot of DEGs in CSDE1 KO Ishikawa cells compared to parental cells. The plot shows log2 fold change on the x-axis and log10 P-value on the y-axis. Red dots represent upregulated genes, green dots represent downregulated genes, and gray dots represent genes with no significant change. B GO analysis of DEGs in parental and CSDE1 KO Ishikawa cells. C KEGG pathway analysis of DEGs in parental and CSDE1 KO Ishikawa cells. D Heatmap of the top 50 DEGs in CSDE1 KO Ishikawa cells compared with parental cells. Red squares represent upregulated genes, and blue squares represent downregulated genes. E RT-qPCR measurement of EMT-related gene mRNA expression in parental and CSDE1 KO Ishikawa cells. Data are shown as mean ± SD (n = 3). F Western blot of the indicated proteins in WCLs from parental and CSDE1 KO Ishikawa cells. G Immunofluorescence analysis of E-cadherin (red) and N-cadherin (green) in parental and CSDE1 KO Ishikawa cells. DAPI was used to stain nuclei (blue). Scale bar, 50 μm. H Representative phase-contrast micrographs illustrating morphological changes induced by CSDE1 KO in Ishikawa cells. Images are shown at ×10 and ×20 magnification. Scale bar, 100 μm. Statistical significance was calculated using the Two-way ANOVA test in E. *p < 0.05. **p < 0.01. ***p < 0.001. ****p < 0.0001. ns, not significant CSDE1 KO induces molecular and morphological changes indicative of EMT in EC cells. A Volcano plot of DEGs in CSDE1 KO Ishikawa cells compared to parental cells. The plot shows log2 fold change on the x-axis and log10 P-value on the y-axis. Red dots represent upregulated genes, green dots represent downregulated genes, and gray dots represent genes with no significant change. B GO analysis of DEGs in parental and CSDE1 KO Ishikawa cells. C KEGG pathway analysis of DEGs in parental and CSDE1 KO Ishikawa cells. D Heatmap of the top 50 DEGs in CSDE1 KO Ishikawa cells compared with parental cells. Red squares represent upregulated genes, and blue squares represent downregulated genes. E RT-qPCR measurement of EMT-related gene mRNA expression in parental and CSDE1 KO Ishikawa cells. Data are shown as mean ± SD (n = 3). F Western blot of the indicated proteins in WCLs from parental and CSDE1 KO Ishikawa cells. G Immunofluorescence analysis of E-cadherin (red) and N-cadherin (green) in parental and CSDE1 KO Ishikawa cells. DAPI was used to stain nuclei (blue). Scale bar, 50 μm. H Representative phase-contrast micrographs illustrating morphological changes induced by CSDE1 KO in Ishikawa cells. Images are shown at ×10 and ×20 magnification. Scale bar, 100 μm. Statistical significance was calculated using the Two-way ANOVA test in E. *p < 0.05. **p < 0.01. ***p < 0.001. ****p < 0.0001. ns, not significant Notably, several hallmark EMT markers, such as CDH2 (N-cadherin), CYR61, CTGF, ANKRD1, and THBS1, were among the most prominently upregulated genes (Fig. 3D). This was further validated by RT-qPCR in both Ishikawa and HEC-1B cells (Fig. 3E, Fig. S2A). At the protein level, Western blot and immunofluorescence analyses confirmed increased expression of N-cadherin and Vimentin in CSDE1 KO Ishikawa cells (Fig. 3F, G). Interestingly, while CDH1 (E-cadherin) mRNA levels remained largely unchanged by RNA-seq analysis, its protein expression was modestly reduced upon CSDE1 loss, suggesting potential post-transcriptional regulation. Consistent with these molecular alterations, phase-contrast microscopy revealed a marked morphological shift, as CSDE1 KO Ishikawa cells transitioned from an epithelial appearance to an elongated, fibroblast-like morphology (Fig. 3H). Similar results in HEC-1B cells underscore the broad impact of CSDE1 on maintaining epithelial identity (Fig. S2B-D). Collectively, these findings demonstrate that CSDE1 loss activates the EMT program, driving the aggressive transformation of EC cells. CSDE1 restricts IL-6 expression via mRNA stability control in EC cells In addition to the EMT-related changes, we noted a dramatic induction of IL-6 expression following CSDE1 KO. Given the pivotal role of IL-6 in promoting inflammation, tumorigenesis, and metastasis, we sought to elucidate the regulatory relationship between CSDE1 and IL-6. RNA-seq analysis revealed a striking 59-fold increase in IL-6 transcript levels in CSDE1 KO Ishikawa cells compared to parental controls (Table S1, Fig. 3D). This finding was robustly validated at both the mRNA and protein levels via RT-qPCR and Western blot analyses (Fig. 4A, B). Furthermore, ELISA assays confirmed a significant surge in secreted IL-6 within the culture supernatants of CSDE1 KO Ishikawa cells (Fig. 4C). Fig. 4CSDE1KO promotes oncogenic phenotypes in EC cells in a partially IL-6-dependent manner. A Western blot of the indicated proteins in WCLs from parental and CSDE1 KO Ishikawa cells. B RT-qPCR measurement of IL-6 mRNA expression in parental and CSDE1 KO Ishikawa cells. Data are presented as mean ± SD (n = 3). C ELISA measurement of IL-6 protein expression in culture supernatants from parental and CSDE1 KO Ishikawa cells. Data are presented as mean ± SD (n = 3). D, E RIP assay analyzing the interaction between CSDE1 and IL-6 mRNA in Ishikawa cells. The RNA-protein complexes were captured using anti-CSDE1 antibody and subsequently measured by qRT-PCR to quantify the enrichment of IL-6 mRNA in the complex (E). Data are presented as mean ± SD (n = 3). F Parental and CSDE1 KO Ishikawa cells were treated with Actinomycin D (5 µg/ml) to inhibit transcription for the indicated time points (0, 1, 2, and 4 h). The remaining IL-6 mRNA levels were quantified by RT-qPCR and normalized to the 0 h time point. Data are presented as mean ± SD (n = 3). G Western blot of the indicated proteins in WCLs from parental and CSDE1 KO Ishikawa cells stably expressing shCtrl, shIL-6-1, or shIL-6-2. H, I Colony formation assay of parental and CSDE1 KO Ishikawa cells stably expressing shCtrl or shIL-6. Quantitative data are shown in (I). Data are presented as mean ± SD (n = 3). J Immunofluorescence analysis of N-cadherin (green) and E-cadherin (red) in parental and CSDE1 KO Ishikawa cells stably expressing shCtrl or shIL-6. Nuclei were stained with DAPI (blue). Scale bar = 50 μm. K, L EdU incorporation assay measuring cell proliferation in parental and CSDE1 KO Ishikawa cells stably expressing shCtrl or shIL-6. Quantitative data are shown in (L). Data are shown as mean ± SD (n = 3). Scale bar = 100 μm. M, N Transwell migration assay of parental and CSDE1 KO Ishikawa cells stably expressing shCtrl or shIL-6. Quantitative data are shown in (N). Data are presented as mean ± SD (n = 3). Scale bar = 100 μm. O, P Transwell invasion assay of parental or CSDE1 KO Ishikawa cells stably expressing shCtrl or shIL-6. Quantitative data are shown in (P). Data are presented as mean ± SD (n = 3). Scale bar = 100 μm. Statistical significance was calculated using the Two-way ANOVA test in (B, C, F, I, L, N, P) and the One-way ANOVA test in (E). *p < 0.05. **p < 0.01. ***p < 0.001. ****p < 0.0001. ns, not significant CSDE1KO promotes oncogenic phenotypes in EC cells in a partially IL-6-dependent manner. A Western blot of the indicated proteins in WCLs from parental and CSDE1 KO Ishikawa cells. B RT-qPCR measurement of IL-6 mRNA expression in parental and CSDE1 KO Ishikawa cells. Data are presented as mean ± SD (n = 3). C ELISA measurement of IL-6 protein expression in culture supernatants from parental and CSDE1 KO Ishikawa cells. Data are presented as mean ± SD (n = 3). D, E RIP assay analyzing the interaction between CSDE1 and IL-6 mRNA in Ishikawa cells. The RNA-protein complexes were captured using anti-CSDE1 antibody and subsequently measured by qRT-PCR to quantify the enrichment of IL-6 mRNA in the complex (E). Data are presented as mean ± SD (n = 3). F Parental and CSDE1 KO Ishikawa cells were treated with Actinomycin D (5 µg/ml) to inhibit transcription for the indicated time points (0, 1, 2, and 4 h). The remaining IL-6 mRNA levels were quantified by RT-qPCR and normalized to the 0 h time point. Data are presented as mean ± SD (n = 3). G Western blot of the indicated proteins in WCLs from parental and CSDE1 KO Ishikawa cells stably expressing shCtrl, shIL-6-1, or shIL-6-2. H, I Colony formation assay of parental and CSDE1 KO Ishikawa cells stably expressing shCtrl or shIL-6. Quantitative data are shown in (I). Data are presented as mean ± SD (n = 3). J Immunofluorescence analysis of N-cadherin (green) and E-cadherin (red) in parental and CSDE1 KO Ishikawa cells stably expressing shCtrl or shIL-6. Nuclei were stained with DAPI (blue). Scale bar = 50 μm. K, L EdU incorporation assay measuring cell proliferation in parental and CSDE1 KO Ishikawa cells stably expressing shCtrl or shIL-6. Quantitative data are shown in (L). Data are shown as mean ± SD (n = 3). Scale bar = 100 μm. M, N Transwell migration assay of parental and CSDE1 KO Ishikawa cells stably expressing shCtrl or shIL-6. Quantitative data are shown in (N). Data are presented as mean ± SD (n = 3). Scale bar = 100 μm. O, P Transwell invasion assay of parental or CSDE1 KO Ishikawa cells stably expressing shCtrl or shIL-6. Quantitative data are shown in (P). Data are presented as mean ± SD (n = 3). Scale bar = 100 μm. Statistical significance was calculated using the Two-way ANOVA test in (B, C, F, I, L, N, P) and the One-way ANOVA test in (E). *p < 0.05. **p < 0.01. ***p < 0.001. ****p < 0.0001. ns, not significant As CSDE1 is a versatile RNA-binding protein frequently involved in modulating mRNA stability, we hypothesized that it might directly regulate IL-6 transcript turnover. RIP assay confirmed a direct interaction between the CSDE1 protein and IL-6 mRNA in Ishikawa cells (Fig. 4D, E). Subsequent Actinomycin D chase assay demonstrated that IL-6 mRNA stability was significantly enhanced in CSDE1KO Ishikawa cells, characterized by an approximately three-fold extension of its transcript half-life compared to parental cells (Fig. 4F). A consistent regulatory effect was similarly observed in HEC-1B cells (Fig. S3A-C). To further substantiate the clinical relevance of the CSDE1–IL-6 regulatory axis, we analyzed the correlation between CSDE1 and IL-6 mRNA expression across multiple independent cohorts. In the CCLE dataset, a significant negative correlation was observed within the endometrial carcinoma cell lines (Spearman’s ρ = -0.330, P = 0.0305; Fig. S3D). This inverse association was consistently validated in the GEO UCEC dataset (GSE115810, Spearman’s ρ = -0.420, P = 0.0292; Fig. S3E). Although this correlation did not reach statistical significance in the larger TCGA-UCEC cohort (Spearman’s ρ =-0.01771, P = 0.6785; Fig. S3F), the discrepancy likely reflects the inherent biological heterogeneity and the confounding influence of IL-6 expression from the tumor stroma in bulk sequencing data. Collectively, these findings establish CSDE1 as a post-transcriptional gatekeeper that restricts IL-6 expression by promoting its mRNA degradation in EC cells. CSDE1 loss drives malignant transformation in EC cells via IL-6 upregulation To determine whether the malignant phenotype induced by CSDE1 loss is mediated by IL-6, we silenced IL-6 in CSDE1 KO Ishikawa cells using lentiviral shRNA and assessed the resulting phenotypic changes. IL-6 silencing effectively reversed the upregulation of EMT markers induced by CSDE1 KO (Fig. 4G). Immunofluorescence analysis confirmed that IL-6 knockdown restored E-cadherin expression and reduced N-cadherin levels in CSDE1 KO Ishikawa cells (Fig. 4J), further supporting a role for IL-6 in EMT regulation. In addition, colony-formation assay demonstrated that IL-6 silencing significantly impaired the enhanced proliferative capacity of CSDE1 KO Ishikawa cells (Fig. 4H, I). EdU incorporation and Transwell migration/invasion assays also showed that IL-6 silencing reversed the increased DNA synthesis (Fig. 4K, L) and cell motility observed in CSDE1 KO Ishikawa cells (Fig. 4M, N). Similar effects were observed in HEC-1B cells, further reinforcing the role of IL-6 in CSDE1-mediated malignant transformation (Fig. S4A-F, S5A-D). Collectively, these results suggest that the aggressive transformation induced by CSDE1 loss in EC is, at least in part, driven by aberrant IL-6 signaling. Siltuximab treatment reverses CSDE1 KO-induced malignant transformation of EC Cells To further validate that the malignant transformation observed in CSDE1 KO EC cells is mediated through IL-6 signaling, we treated CSDE1 KO Ishikawa cells with Siltuximab, a monoclonal antibody that specifically neutralizes IL-6. Siltuximab, also known as CNTO 328, has been reported to block IL-6–induced STAT3 phosphorylation and STAT3 nuclear translocation, and to reduce STAT3 downstream anti-apoptotic proteins such as MCL-1, Bcl-XL, and survivin in ovarian cancer cells. Therefore, this experiment was designed to determine whether IL-6 signaling is required for the enhanced malignant phenotype induced by CSDE1 loss. Siltuximab treatment significantly attenuated cell proliferation, as evidenced by a marked reduction in colony formation and DNA synthesis (assessed via EdU incorporation). Furthermore, both the migratory and invasive capacities of CSDE1 KO Ishikawa cells were effectively suppressed upon IL-6 neutralization (Fig. 5A-H, Fig. S5E-L). In vivo experiments further substantiated these findings. While xenograft tumors derived from CSDE1 KO Ishikawa cells exhibited significantly accelerated growth compared to parental controls in nude mice, Siltuximab administration markedly inhibited this tumor progression (Fig. 5I-K). These results underscore the critical role of IL-6 in mediating the tumor-promoting effects of CSDE1 deficiency in vivo. Collectively, these findings demonstrate that pharmacological blockade of the IL-6 can reverse CSDE1 loss-induced malignant traits, highlighting the therapeutic potential of IL-6 targeting in CSDE1-deficient EC. Fig. 5IL-6 Inhibition reverses CSDE1KO–induced malignant phenotypes in EC cells. A, B Colony formation assay of parental and CSDE1 KO Ishikawa cells treated with PBS or Siltuximab (10 ng/ml). Quantitative data are shown in B. Data are shown as means ± SD (n = 3). C, D EdU incorporation assay of parental and CSDE1 KO Ishikawa cells treated with PBS or Siltuximab (10 ng/ml) for 24 h. Quantitative data are shown in D. Data are shown as the mean ± SD (n = 3). Scale bar, 100 μm. E, F Transwell invasion assay of parental and CSDE1 KO Ishikawa cells treated with PBS or Siltuximab (10 ng/ml). Quantitative data are presented in F. Data are expressed as the mean ± SD (n = 3). Scale bar, 100 μm. G, H Transwell invasion assay of parental and CSDE1 KO Ishikawa cells treated with Siltuximab (10 ng/ml). Quantitative data are presented in H. Data are expressed as the mean ± SD (n = 3). Scale bar, 100 μm. I, J In vivo xenograft tumor assay. Parental or CSDE1 KO Ishikawa cells were subcutaneously injected into BALB/c nude mice. Once tumor volumes reached approximately 50 mm³, mice were treated with either PBS or Siltuximab (10 mg/kg). I Representative images of harvested tumors at day 25 post-implantation. J Tumor growth curves monitored every 3 days. K Statistical analysis of terminal tumor weights at day 25. Data are shown as means ± SD (n = 6). Statistical significance was calculated using the Two-way ANOVA test in (B, D, F, H, J, K). *p < 0.05. **p < 0.01. ***p < 0.001. ****p < 0.0001. ns, not significant IL-6 Inhibition reverses CSDE1KO–induced malignant phenotypes in EC cells. A, B Colony formation assay of parental and CSDE1 KO Ishikawa cells treated with PBS or Siltuximab (10 ng/ml). Quantitative data are shown in B. Data are shown as means ± SD (n = 3). C, D EdU incorporation assay of parental and CSDE1 KO Ishikawa cells treated with PBS or Siltuximab (10 ng/ml) for 24 h. Quantitative data are shown in D. Data are shown as the mean ± SD (n = 3). Scale bar, 100 μm. E, F Transwell invasion assay of parental and CSDE1 KO Ishikawa cells treated with PBS or Siltuximab (10 ng/ml). Quantitative data are presented in F. Data are expressed as the mean ± SD (n = 3). Scale bar, 100 μm. G, H Transwell invasion assay of parental and CSDE1 KO Ishikawa cells treated with Siltuximab (10 ng/ml). Quantitative data are presented in H. Data are expressed as the mean ± SD (n = 3). Scale bar, 100 μm. I, J In vivo xenograft tumor assay. Parental or CSDE1 KO Ishikawa cells were subcutaneously injected into BALB/c nude mice. Once tumor volumes reached approximately 50 mm³, mice were treated with either PBS or Siltuximab (10 mg/kg). I Representative images of harvested tumors at day 25 post-implantation. J Tumor growth curves monitored every 3 days. K Statistical analysis of terminal tumor weights at day 25. Data are shown as means ± SD (n = 6). Statistical significance was calculated using the Two-way ANOVA test in (B, D, F, H, J, K). *p < 0.05. **p < 0.01. ***p < 0.001. ****p < 0.0001. ns, not significant Discussion CSDE1 mutations have been implicated in various neurodevelopmental and psychiatric disorders, including autism spectrum disorder [30], intellectual disability [31], and psychosis [32, 33]. Furthermore, CSDE1 has been associated with hematologic and cardiovascular diseases [34]. The oncological relevance of CSDE1, first suggested in 1997 [35], has been increasingly recognized, with evidence showing its ability to govern cell survival by fine-tuning proto-oncogenes and cell cycle regulators [36, 37]. In certain contexts, such as squamous cell carcinoma, CSDE1 acts as a tumor suppressor by reprogramming the translational landscape—specifically by inhibiting YBX1 and stabilizing SASP-related mRNAs to drive cellular senescence [38]. Its interaction with the compound clofoctol in glioma further highlights its druggability and importance as a potential therapeutic target [30, 39]. In the present study, we demonstrate that the loss of CSDE1 in EC cells markedly enhances cellular proliferation, migration, and invasiveness. Our findings reveal that CSDE1 governs EC progression by modulating the post-transcriptional stability of interleukin-6 (IL-6) mRNA. As a pleiotropic cytokine, IL-6 is a pivotal driver in multiple malignancies, where it sustains a chronic inflammatory landscape within the tumor microenvironment (TME) to promote tumorigenesis [40]. Persistent IL-6 signaling actively reshapes the TME [41, 42] ], thereby fostering immune evasion, malignant progression, and systemic dissemination [43]. By orchestrating several signaling cascades [44] —most notably the JAK/STAT3, PI3K/Akt, and MAPK pathways—IL-6 drives the expression of critical oncogenic effectors, including c-MYC, BCL2, and Cyclin D1 [24, 45], which collectively underpin tumor survival and metastasis. As a versatile RNA-binding protein (RBP), CSDE1 orchestrates the post-transcriptional landscape by modulating the stability and translation of hundreds of mRNA targets [46, 47], with its regulatory effects being highly context-dependent. CSDE1 has been implicated in governing several hallmarks of cancer—as defined by Hanahan [48], —including proliferation, survival, invasion, senescence, and immune evasion [49]. High-throughput studies have revealed that CSDE1 interacts with thousands of mRNA transcripts; however, the striking variation in its targets across different cell types underscores its functional plasticity [5, 50]. For instance, in melanoma, CSDE1 enhances invasiveness by downregulating PTEN mRNA while concurrently promoting the translation of PTPN2 and PMEPA1 [7, 38, 51]. Furthermore, CSDE1 facilitates immune evasion by stabilizing PTPN2 mRNA, which encodes the STAT1 phosphatase TCPTP [52]. Our study identifies IL-6 as a novel and critical target of CSDE1 in EC. We demonstrate that CSDE1 directly binds to IL-6 mRNA and negatively regulates its stability, thereby serving as a post-transcriptional gatekeeper of IL-6 expression. The loss of CSDE1 increases IL-6 mRNA stability, leading to an inflammatory surge that drives the aggressive phenotypes observed in CSDE1-deficient EC cells. Notably, pharmacological neutralization of IL-6 with the monoclonal antibody Siltuximab effectively reversed these malignant traits, suggesting that targeting the IL-6 signaling axis represents a promising precision-medicine strategy for EC patients harboring CSDE1 deficiency. In the present study, we utilized a gene knockout approach to model the loss-of-function effects of CSDE1, which reflects the likely impact of the significant proportion of truncating mutations identified in EC. While this approach clarifies the tumor-suppressive role of CSDE1 loss, the specific functional consequences of missense mutations—which may involve altered protein stability or atypical signaling—remain to be fully explored. Future investigations employing site-directed mutagenesis and functional rescue assays will be instrumental in dissecting the precise molecular mechanisms by which different CSDE1 mutation subtypes contribute to EC pathogenesis. In summary, our study elucidates a novel molecular mechanism by which CSDE1 loss drives malignant progression in EC through the post-transcriptional regulation of IL-6 mRNA stability. By defining the CSDE1–IL-6 signaling axis, we identify a critical therapeutic vulnerability in this patient subset. These findings not only provide a framework for future investigations into CSDE1-deficient malignancies but also expand our understanding of how RNA-binding proteins orchestrate inflammatory cytokine signaling during cancer progression (Fig. 6). Fig. 6Schematic representation of the CSDE1–IL-6 regulatory axis in EC. CSDE1 acts as a post-transcriptional suppressor by binding to and facilitating the degradation of IL-6 mRNA. In CSDE1-deficient cells, the loss of this regulatory mechanism stabilizes IL-6 transcripts, resulting in heightened cytokine secretion that fuels tumor cell proliferation, migration, and invasion. Pharmacological inhibition of IL-6 signaling with Siltuximab effectively abrogates these malignant phenotypes, revealing a targetable therapeutic vulnerability in CSDE1-deficient EC Schematic representation of the CSDE1–IL-6 regulatory axis in EC. CSDE1 acts as a post-transcriptional suppressor by binding to and facilitating the degradation of IL-6 mRNA. In CSDE1-deficient cells, the loss of this regulatory mechanism stabilizes IL-6 transcripts, resulting in heightened cytokine secretion that fuels tumor cell proliferation, migration, and invasion. Pharmacological inhibition of IL-6 signaling with Siltuximab effectively abrogates these malignant phenotypes, revealing a targetable therapeutic vulnerability in CSDE1-deficient EC Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2. Supplementary Material 3. Supplementary Material 3.